Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
Open Access
- 2 January 2023
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 41 (6) , 783-787
Abstract
Cancer neoantigens that arise from tumor mutations are drivers of tumor-specific T cell responses, but identification of T cell-recognized neoantigens in individual patients is challenging. Previous methods have restricted antigen discovery to selected HLA alleles, thereby limiting the breadth of neoantigen repertoires that can be uncovered. Here, we develop a genetic neoantigen screening system that allows sensitive identification of CD4+ and CD8+ T cell-recognized neoantigens across patients’ complete HLA genotypes.Keywords
This publication has 32 references indexed in Scilit:
- Targeting of cancer neoantigens with donor-derived T cell receptor repertoiresScience, 2016
- Immunogenicity of somatic mutations in human gastrointestinal cancersScience, 2015
- Neoantigens in cancer immunotherapyScience, 2015
- High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanomaNature Medicine, 2014
- Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor RegressionsClinical Cancer Research, 2014
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience, 2014
- TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct MechanismsThe Journal of Immunology, 2011
- Generation of stable monoclonal antibody–producing B cell receptor–positive human memory B cells by genetic programmingNature Medicine, 2009
- Selecting highly affine and well-expressed TCRs for gene therapy of melanomaBlood, 2007
- Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating LymphocytesThe Journal of Immunology, 2006